Honors & Awards

  • Interventional Oncology Essentials Scholarship Award, Society of Interventional Oncology (SIO) (2024)
  • Residents and Fellows Activity Scholarship, International Symposium on Endovascular Therapy (ISET) (2024)
  • 2023 Annual Meeting Registration Scholarship, American Society of Emergency Radiology (ASER) (2023)
  • Interventional Oncology Essentials Scholarship Award, Society of Interventional Oncology (SIO) (2023)
  • Physician-in-Training Scholarship, SPECTRUM (2023)
  • Residents & Fellows Activity Scholarship, International Symposium on Endovascular Therapy (ISET) (2023)
  • 2022 Outstanding Presentation Award, American Society of Neuroradiology (ASNR) (2022)
  • CIO Residents/Fellows Activity Scholarship, Clinical Interventional Oncology (CIO) (2022)
  • Residents and Fellows Activity Scholarship, International Symposium on Endovascular Therapy (ISET) (2022)
  • Steven M. Pinsky Resident Poster Award, Chicago Radiological Society (CRS) (2022)
  • Trainee Scholarship, Global Embolization Oncology Symposium Technologies (GEST) (2022)
  • Trainee Scholarship, Global Embolization Oncology Symposium Technologies (GEST) (2021)
  • Gold Medal Winner for securing highest marks in Surgery University Examination, Vinayaka Missions Research Foundation (2018)
  • 1st Place, 30th Indian Academy of Pediatrics (IAP) Quiz (2017)
  • Travel Grant, Nichi-In Centre for Regenerative Medicine (NCRM) Fujio Cup Quiz, Tokyo, Japan (2017)
  • 1st Place, Indian Association of Preventive and Social Medicine (IAPSM) –World Health Day Quiz 2016 (2016)
  • Finalist, Elsevier Basic Sciences Olympiad (EBSO) INDIA Grand Finale (2014-2015)

Boards, Advisory Committees, Professional Organizations

  • Chair, Research & Innovation (R&I) Committee, Resident and Fellow Section (RFS), Society of Interventional Radiology (SIR) (2023 - Present)
  • Co-Chair, Stanford University Postdoctoral Association (SURPAS) Postdoc Symposium Committee (2022 - Present)
  • Member, NCI Co-Clinical Imaging Research Program (CIRP) Informatics and Outreach (IMOR) Workgroup (2022 - Present)
  • Steering Committee member, The National Cancer Institute (NCI) Co-Clinical Imaging Research Program (CIRP) (2022 - Present)
  • Member, Society of Interventional Radiology (SIR) Connect Moderation Review Committee (2021 - Present)
  • Chair, Women in IR (WIR) Committee, Resident and Fellow Section (RFS), Society of Interventional Radiology (2021 - 2023)

All Publications

  • Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet. Rheumatology 2023; 5 (11): e670-e682


    Musculoskeletal disorders include more than 150 different conditions affecting joints, muscles, bones, ligaments, tendons, and the spine. To capture all health loss from death and disability due to musculoskeletal disorders, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) includes a residual musculoskeletal category for conditions other than osteoarthritis, rheumatoid arthritis, gout, low back pain, and neck pain. This category is called other musculoskeletal disorders and includes, for example, systemic lupus erythematosus and spondylopathies. We provide updated estimates of the prevalence, mortality, and disability attributable to other musculoskeletal disorders and forecasted prevalence to 2050.Prevalence of other musculoskeletal disorders was estimated in 204 countries and territories from 1990 to 2020 using data from 68 sources across 23 countries from which subtraction of cases of rheumatoid arthritis, osteoarthritis, low back pain, neck pain, and gout from the total number of cases of musculoskeletal disorders was possible. Data were analysed with Bayesian meta-regression models to estimate prevalence by year, age, sex, and location. Years lived with disability (YLDs) were estimated from prevalence and disability weights. Mortality attributed to other musculoskeletal disorders was estimated using vital registration data. Prevalence was forecast to 2050 by regressing prevalence estimates from 1990 to 2020 with Socio-demographic Index as a predictor, then multiplying by population forecasts.Globally, 494 million (95% uncertainty interval 431-564) people had other musculoskeletal disorders in 2020, an increase of 123·4% (116·9-129·3) in total cases from 221 million (192-253) in 1990. Cases of other musculoskeletal disorders are projected to increase by 115% (107-124) from 2020 to 2050, to an estimated 1060 million (95% UI 964-1170) prevalent cases in 2050; most regions were projected to have at least a 50% increase in cases between 2020 and 2050. The global age-standardised prevalence of other musculoskeletal disorders was 47·4% (44·9-49·4) higher in females than in males and increased with age to a peak at 65-69 years in male and female sexes. In 2020, other musculoskeletal disorders was the sixth ranked cause of YLDs globally (42·7 million [29·4-60·0]) and was associated with 83 100 deaths (73 600-91 600).Other musculoskeletal disorders were responsible for a large number of global YLDs in 2020. Until individual conditions and risk factors are more explicitly quantified, policy responses to this burden remain a challenge. Temporal trends and geographical differences in estimates of non-fatal disease burden should not be overinterpreted as they are based on sparse, low-quality data.Bill & Melinda Gates Foundation.

    View details for DOI 10.1016/S2665-9913(23)00232-1

    View details for PubMedID 37927903

    View details for PubMedCentralID PMC10620749

  • ChatGPT and the Reshaping of Radiology Training RADIOLOGY Ramasamy, S. 2023; 307 (5)
  • Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration. Journal of visualized experiments : JoVE Ramasamy, S. K., Roudi, R., Morakote, W., Adams, L. C., Pisani, L. J., Moseley, M., Daldrup-Link, H. E. 2023


    T2* relaxometry is one of the established methods to measure the effect of superparamagnetic iron oxide nanoparticles on tumor tissues with magnetic resonance imaging (MRI). Iron oxide nanoparticles shorten the T1, T2, and T2* relaxation times of tumors. While the T1 effect is variable based on the size and composition of the nanoparticles, the T2 and T2* effects are usually predominant, and T2* measurements are the most time-efficient in a clinical context. Here, we present our approach to measuring tumor T2* relaxation times, using multi-echo gradient echo sequences, external software, and a standardized protocol for creating a T2* map with scanner-independent software. This facilitates the comparison of imaging data from different clinical scanners, different vendors, and co-clinical research work (i.e., tumor T2* data obtained in mouse models and patients). Once the software is installed, the T2 Fit Map plugin needs to be installed from the plugin manager. This protocol provides step-by-step procedural details, from importing the multi-echo gradient echo sequences into the software, to creating color-coded T2* maps and measuring tumor T2* relaxation times. The protocol can be applied to solid tumors in any body part and has been validated based on preclinical imaging data and clinical data in patients. This could facilitate tumor T2* measurements for multi-center clinical trials and improve the standardization and reproducibility of tumor T2* measurements in co-clinical and multi-center data analyses.

    View details for DOI 10.3791/64773

    View details for PubMedID 37318243

  • Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art. AJR. American journal of roentgenology Adams, L. C., Jayapal, P., Ramasamy, S. K., Morakote, W., Yeom, K., Baratto, L., Daldrup-Link, H. E. 2022


    Ferumoxytol is an ultrasmall iron oxide nanoparticle, originally approved in 2009 by the FDA for IV treatment of iron deficiency in adults with chronic kidney disease. Subsequently, its off-label use as an MRI contrast agent has increased in clinical practice, particularly in pediatric patients in North America. Unlike conventional MRI contrast agents that are based on the rare earth metal gadolinium [gadolinium-based contrast agents (GBCAs)], ferumoxytol is biodegradable and carries no potential risk of nephrogenic systemic fibrosis. At FDA-approved doses, ferumoxytol demonstrates no long-term tissue retention in patients with intact iron metabolism. Ferumoxytol provides unique MRI properties including long-lasting vascular retention (facilitating high-quality vascular imaging) and retention in reticuloendothelial system tissues, thereby supporting a variety of applications beyond those possible with GBCAs. This Clinical Perspective describes clinical and early translational applications of ferumoxytol-enhanced MRI in children and young adults through off-label use for a variety of settings, including vascular, cardiac, and cancer imaging, drawing on the authors' institutional experience. In addition, we describe current preclinical and clinical research advances using ferumoxytol with regard to cellular and molecular imaging, and also as a novel potential cancer therapeutic agent.

    View details for DOI 10.2214/AJR.22.28453

    View details for PubMedID 36197052

  • Women in academic radiology: comparative analysis of leadership in interventional and diagnostic radiology Society of Interventional Radiology (SIR) Annual Scientific Meeting Tafreshi, S., Le, R., Ramasamy, S., Choudhury, P., Goldman, D., Hamilton, B. 2022: S131
  • Enhancement conspicuity of Hepatocellular Carcinoma is decreased in the presence of Transjugular Intrahepatic Portosystemic Shunts Global Embolization Symposium & Technologies (GEST) Ramasamy, S., Ploussard, B., Lovrec, P., Ness, J., Sullivan, I., Jawahar, A., Molvar, C. 2022: e23
  • Transvenous embolization of cerebrospinal fluid–venous fistula (CVF): a systematic review Global Embolization Symposium & Technologies (GEST) Ramasamy, S. 2022: e48
  • Endovascular Treatment of Infected Superior Mesenteric Artery Aneurysm: A Case Report and Systematic Review The International Symposium on Endovascular Therapy (ISET) Ramasamy, S., Ahmed, O. 2022: e9
  • Endovascular treatment of Infected SMA Aneurysm: A case report and systematic review. The International Symposium on Endovascular Therapy (ISET) Ramasamy, S., Ahmed, O. 2022: e9
  • Segmental Yttrium-90 Radioembolization as an Initial Treatment for Solitary Unresectable HCC The Arab Journal of Interventional Radiology Rothenberger, N., Yu, Q., Ramasamy, S., Van Ha, T., Zangan,, ., Navuluri, R., Ahmed, O. 2022; 06 (02)

    View details for DOI 10.1055/s-0042-1758698